MannKind Corporation announced that David M. Kendall, MD, will join the company as Chief Medical Officer and assume full responsibility for leading MannKind’s scientific research, clinical development, regulatory, and medical affairs activity, effective February 12, 2018. Dr. Kendall will report directly to Michael Castagna, Pharm.D., Chief Executive Officer, and will join the company's executive leadership team. He will be based out of MannKind’s Westlake Village, California headquarters. Most recently, he served as Research Physician and Vice President of Global Medical Affairs for Lilly Diabetes, and during that time was responsible for all medical affairs activities and guided research and development strategy across multiple geographies. Prior to joining Eli Lilly, Dr. Kendall served as Chief Scientific and Medical Officer at the American Diabetes Association, where he was responsible for all medical affairs, medical education, research, outcomes, and medical policy activities. Earlier in his career, Dr. Kendall served as Medical Director at the International Diabetes Center, and the Park Nicollet Clinic, as well as at Amylin Pharmaceuticals.